

Supplementary Table 1. Baseline characteristics of patients with biopsy-proven NAFLD, stratified by genotypes of *CYP2E1* rs2070673

SNP	rs2070673								
Genotype	AA	TA	<i>P</i> -value	AA	TT	<i>P</i> -value	TA	TT	<i>P</i> -value
<i>N</i>	59	221		59	158		221	158	
Clinical characteristics									
Age (years)	40 ± 13	41 ± 13	0.90	40 ± 13	42 ± 13	0.33	41 ± 13	42 ± 13	0.21
Male sex, n (%)	42 (71.2%)	163 (73.8%)	0.69	42 (71.2%)	110 (69.6%)	0.82	163 (73.8%)	110 (69.6%)	0.38
Total bilirubin (mmol/L)	13 ± 6	14 ± 6	0.20	13 ± 6	14 ± 7	0.43	14 ± 6	14 ± 7	0.46
Albumin (g/L)	45.5 ± 4.0	46.1 ± 4.3	0.25	45.5 ± 4.0	46.3 ± 3.7	0.29	46.1 ± 4.3	46.3 ± 3.7	0.89
ALT (U/L)	55.0 (35.0-84.5)	57.0 (36.0-102.0)	0.44	55.0 (35.0-84.5)	52.5 (28.0-87.0)	0.39	57.0 (36.0-102.0)	52.5 (28.0-87.0)	0.02
ALP (U/L)	81 ± 24	85 ± 23	0.09	81 ± 24	83 ± 22	0.32	85 ± 23	83 ± 22	0.33
GGT (U/L)	61.6 ± 39.9	71.9 ± 54.0	0.26	61.6 ± 39.9	61.6 ± 43.5	0.70	71.9 ± 54.0	61.6 ± 43.5	0.04
Fasting glucose (mmol/L)	5.6 ± 1.3	5.9 ± 1.7	0.28	5.6 ± 1.3	5.7 ± 1.4	0.57	5.9 ± 1.7	5.7 ± 1.4	0.49
Creatinine (mmol/L)	67 ± 15	67 ± 14	0.88	67 ± 15	68 ± 16	0.72	67 ± 14	68 ± 16	0.71
Uric acid (mmol/L)	401 ± 115	398 ± 100	0.99	401 ± 115	396 ± 117	0.74	398 ± 100	396 ± 117	0.53
Total cholesterol (mmol/L)	5.26 ± 1.18	5.07 ± 1.15	0.37	5.26 ± 1.18	5.12 ± 1.16	0.57	5.07 ± 1.15	5.12 ± 1.16	0.70
Triglycerides (mmol/L)	2.28 (1.69-3.28)	1.90 (1.37-2.84)	0.03	2.28 (1.69-3.28)	1.88 (1.37-2.59)	0.01	1.90 (1.37-2.84)	1.88 (1.37-2.59)	0.64
HDL-cholesterol (mmol/L)	0.99 ± 0.25	1.00 ± 0.21	0.37	0.99 ± 0.25	0.99 ± 0.21	0.48	1.00 ± 0.21	0.99 ± 0.21	0.76
LDL-cholesterol (mmol/L)	3.16 ± 0.92	3.02 ± 0.94	0.35	3.16 ± 0.92	3.08 ± 0.90	0.59	3.02 ± 0.94	3.08 ± 0.90	0.55
HOMA-IR score	3.3 (2.8-5.6)	3.5 (2.6-5.0)	0.80	3.3 (2.8-5.6)	3.9 (2.4-5.3)	0.97	3.5 (2.6-5.0)	3.9 (2.4-5.3)	0.72

HOMA-IR score ≥ 2.7 , n (%)	43 (76.8%)	152 (71.7%)	0.45	43 (76.8%)	105 (68.6%)	0.25	152 (71.7%)	105 (68.6%)	0.53
BMI (kg/m ²)	26.8 \pm 3.2	27.1 \pm 3.3	0.56	26.8 \pm 3.2	26.9 \pm 3.5	0.78	27.1 \pm 3.3	26.9 \pm 3.5	0.72
Comorbidity									
Hypertension, n (%)	21 (35.6%)	67 (30.3%)	0.44	21 (35.6%)	54 (34.2%)	0.85	67 (30.3%)	54 (34.2%)	0.43
Type 2 diabetes, n (%)	17 (28.8%)	75 (33.9%)	0.46	17 (28.8%)	52 (32.9%)	0.56	75 (33.9%)	52 (32.9%)	0.84
Dyslipidemia, n (%)	51 (86.4%)	203 (92.7%)	0.13	51 (86.4%)	143 (91.1%)	0.32	203 (92.7%)	143 (91.1%)	0.57
Central obesity, n (%)	41 (71.9%)	164 (75.9%)	0.54	41 (71.9%)	112 (73.7%)	0.80	164 (75.9%)	112 (73.7%)	0.63
Liver histology features									
Moderate/severe steatosis, n(%)	33 (55.9%)	148 (67.0%)	0.12	33 (55.9%)	88 (55.7%)	0.98	148 (67.0%)	88 (55.7%)	0.03
Presence of ballooning, n(%)	49 (83.1%)	194 (87.8%)	0.34	49 (83.1%)	136 (86.1%)	0.58	194 (87.8%)	136 (86.1%)	0.63
Moderate/severe lobular Inflammation, n(%)	12 (20.3%)	61 (27.6%)	0.26	12 (20.3%)	21 (13.3%)	0.20	61 (27.6%)	21 (13.3%)	<0.01
Definite NASH, n(%)	25 (42.4%)	123 (55.7%)	0.07	25 (42.4%)	64 (40.5%)	0.80	123 (55.7%)	64 (40.5%)	<0.01
Presence of any stage of fibrosis, n (%)			0.65			0.91			0.55
0	16 (27.1%)	47 (21.3%)		16 (27.1%)	39 (24.7%)		47 (21.3%)	39 (24.7%)	
1	29 (49.2%)	120 (54.3%)		29 (49.2%)	76 (48.1%)		120 (54.3%)	76 (48.1%)	
2	11 (18.6%)	40 (18.1%)		11 (18.6%)	36 (22.8%)		40 (18.1%)	36 (22.8%)	

3	2 (3.4%)	13 (5.9%)	2 (3.4%)	6 (3.8%)	13 (5.9%)	6 (3.8%)
4	1 (1.7%)	1 (0.5%)	1 (1.7%)	1 (0.6%)	1 (0.5%)	1 (0.6%)

Categorical values are shown as n (%). Continuous variables are shown as mean \pm SD or median (Q1-Q3). For the sake of clarity, significant p values were highlighted in bold italics.

Abbreviations: CYP2E1, cytochrome P450-2E1; BMI, body mass index; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, γ -glutamyltranspeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance.